<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252992</url>
  </required_header>
  <id_info>
    <org_study_id>P081253</org_study_id>
    <secondary_id>2010-A00375-34</secondary_id>
    <nct_id>NCT01252992</nct_id>
  </id_info>
  <brief_title>Paradoxical Reactions in Non Immuno-compromized Patients With Extrapulmonary Tuberculosis</brief_title>
  <acronym>PARATB</acronym>
  <official_title>Paradoxical Reactions During Anti-mycobacterial Treatment of Extrapulmonary Tuberculosis in Non Immuno-compromized Patients : Clinical, Radiological et Immunological</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculous paradoxical reactions (PR) are immune reactions occurring during the course of&#xD;
      antituberculous treatment and leading to a worsening of tuberculous symptoms after an initial&#xD;
      improvement. This phenomenon has very extensively studied in HIV infected patients where it&#xD;
      corresponds to the so called IRIS (immune reconstitution syndrome). However, it laso occurs&#xD;
      in non immuno-compromized patients, especially those with extra-pulmonary localization of&#xD;
      tuberculosis. The aim of the study is to look for risk factors of paradoxical reaction in non&#xD;
      immuno-compromized patients with extra-pulmonary tuberculosis. The investigators will&#xD;
      consider clinical, radiological and biological variables, including specific immune and&#xD;
      genetic markers. Our secondary goals are to estimate the incidence of PR, describe their&#xD;
      natural history; characterize the type of immune response they correspond to, and look for&#xD;
      better diagnostic tools.The immunological characterization and the finding of predictive&#xD;
      factors of PR, especially the genetic ones will allow a better understanding of biological&#xD;
      mechanisms that lead to their occurrence during extra-pulmonary tuberculosis treatment. The&#xD;
      establishment of predictive criteria could permit a better surveillance of at risk patients&#xD;
      for a rapid treatment, or even a prevention of PR. The establishment of new diagnostic&#xD;
      criteria at the time of PR could avoid numerous invasive diagnostic procedures, surgery&#xD;
      and/or useless prolongation of antibiotic treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective :&#xD;
&#xD;
      Search for predictive factors of tuberculous paradoxical reaction (PR), with assessment of&#xD;
      clinical, radiological and biological factors.&#xD;
&#xD;
      Secondary objectives :&#xD;
&#xD;
        -  Descriptive study of PR : incidence, clinical and radiological presentation, clinical&#xD;
           course ; characterization of mycobacteria strains- Search for genetic predictive factors&#xD;
           of PR&#xD;
&#xD;
        -  Characterization of the specific immune antigene response during PR et analysis of&#xD;
           different cell subsets implicated in peripheral blood and locally- Characterization of&#xD;
           the anti-bacterial immune response before and after antituberculous treatment&#xD;
&#xD;
        -  Preliminary search for new diagnosis criteria including clinical, biological (immune and&#xD;
           genetic) and radiological factors.Methodology : Multicentric cohort study for a total of&#xD;
           5 years (4 years of enrolment and one year of follow-up, with biological collection for&#xD;
           scientific purpose&#xD;
&#xD;
      Inclusion Status of patients (determined by a validation comity at M6)&#xD;
&#xD;
        -  PR+ : PR with clinical symptoms&#xD;
&#xD;
        -  rPR : pure radiological PR&#xD;
&#xD;
        -  PR- : absence of RP after 6 months of treatment Development of the study&#xD;
&#xD;
      Primary outcome :&#xD;
&#xD;
      - Association between PR+ occurrence and clinical, biological and radiological factors&#xD;
      harvested at the diagnosis of tuberculosis..&#xD;
&#xD;
      Secondary outcomes :&#xD;
&#xD;
        -  Association between PR+ and rPR&#xD;
&#xD;
        -  occurrence and the above quoted factors.- Descriptive study : clinical, biological, and&#xD;
           radiological presentation of PR+ and rPR, characterization of isolated BK strains in PR+&#xD;
           patients&#xD;
&#xD;
        -  Immunological study in 20 PR+ patients and 20 RP- : 20 patients per group will allow a&#xD;
           80% power to detect, by means of bilateral Mann-Whitney test with alpha=5%, any&#xD;
           difference in the count of specific cells corresponding to at least one standard&#xD;
           deviation of the primary immunological outcome&#xD;
&#xD;
        -  controls: variation between tuberculosis diagnostic and either PR time or M2 (in absence&#xD;
           of PR), of the specific cells, macrophages, dendritic cells, gamma-delta lymphocytes, NK&#xD;
           et CD4 cells counts&#xD;
&#xD;
        -  Preliminary search for diagnostic criteria that can be used at the time of PR&#xD;
           occurrence: variation between D0 and the PR of clinical, biological, radiological&#xD;
           immunological et genomic of PR+ patients.&#xD;
&#xD;
        -  Evolution specific and non specific immune response of mycobacterial antigen at&#xD;
           tuberculosis diagnosis during tuberculosis treatment and after. Sample size calculation&#xD;
&#xD;
        -  prognostic study : Patients will be recruited and followed until the achievement of a 20&#xD;
           PR+ sample. The investigators will have to analyze 200 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2011</start_date>
  <completion_date type="Actual">February 21, 2018</completion_date>
  <primary_completion_date type="Actual">February 21, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk factors of paradoxical reaction</measure>
    <time_frame>at 6 months</time_frame>
    <description>Risk factors of paradoxical reaction : clinical, radiological immune and genetic factors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and natural history of paradoxical reactions</measure>
    <time_frame>during the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune description of paradoxical reactions</measure>
    <time_frame>during the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary study of Diagnosis factors of paradoxical reaction</measure>
    <time_frame>during the first 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">135</enrollment>
  <condition>Extrapulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1:paradoxical reaction negative (RP-)</arm_group_label>
    <description>control group with tuberculosis but without paradoxical reaction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1:paradoxical reaction negative (RP+)</arm_group_label>
    <description>group with tuberculosis and paradoxical reaction</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic analysis</intervention_name>
    <description>identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;&#xD;
Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.&#xD;
One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction.</description>
    <arm_group_label>1:paradoxical reaction negative (RP+)</arm_group_label>
    <arm_group_label>1:paradoxical reaction negative (RP-)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM</intervention_name>
    <description>at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist</description>
    <arm_group_label>1:paradoxical reaction negative (RP+)</arm_group_label>
    <arm_group_label>1:paradoxical reaction negative (RP-)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immunologic analysis</intervention_name>
    <description>For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+</description>
    <arm_group_label>1:paradoxical reaction negative (RP+)</arm_group_label>
    <arm_group_label>1:paradoxical reaction negative (RP-)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QuantiferonTB Gold test</intervention_name>
    <description>at M0, M2, M6 and in case of PR+.</description>
    <arm_group_label>1:paradoxical reaction negative (RP+)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples (immunologic test), DNA, RNA, Biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Extra-pulmonary tuberculosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Extrapulmonary tuberculosis, with associated pulmonary localization or not&#xD;
&#xD;
          -  Treatment started less than 5 days ago&#xD;
&#xD;
          -  Negative HIV serology&#xD;
&#xD;
          -  Social insurance&#xD;
&#xD;
          -  Age &gt;= 18- Foreseeable follow-up of at last one year&#xD;
&#xD;
          -  Signed Free Inform Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  immuno-suppressive treatment (including corticosteroids &gt; 10 mg /d prednisone&#xD;
             equivalent, however patients with corticotherapy could be included during the phase 2&#xD;
             of the study)&#xD;
&#xD;
          -  central neurological system tuberculosis and tuberculous pericarditis - pure pulmonary&#xD;
             tuberculosis&#xD;
&#xD;
          -  multiresistant tuberculosis&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne BOURGARIT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georges Pompidou Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 27, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extrapulmonary</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Paradoxical reaction</keyword>
  <keyword>Risk factors</keyword>
  <keyword>Incidence</keyword>
  <keyword>CT scan</keyword>
  <keyword>Natural history</keyword>
  <keyword>Immune system phenomena</keyword>
  <keyword>Immune markers</keyword>
  <keyword>Gene Expression Profiling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

